Researchers found that sargramostim decreased UCH-L1 and total tau levels in mild-to-moderate Alzheimer’s patients. MMSE cognitive scores improved, and mouse models confirmed reduced neuronal ...

With a pivotal trial readout for Cognito’s Spectris due later this year, the company anticipates launching the Alzheimer’s disease therapeutic in the US by 2027.

A recent study shows that combining magnetic brain scans with computer models can safely measure how dementia medications affect living human brains. This approach could replace invasive tests and ...

Dr Ray O’Connor takes a look at the latest clinical studies on dementia, including its diagnosis and management ...

Lower eGFR and higher urinary protein-to-creatinine ratio were associated with greater risks for cognitive impairment across the chronic kidney disease spectrum, according to study data published in ...

Being in a more advanced stage of chronic kidney disease (CKD) comes with an increased risk of cognitive impairment among patients with CKD, according to a February study published in the JAMA Network ...

A person’s combined physical and mental strength can predict their risk of developing memory problems later in life. New ...

Middle-aged adults should be tested for a gene that could be responsible for more than 90 percent of Alzheimer's cases, a new ...

Advanced proteomics and AI reveal blood protein changes, offering insights into early Alzheimer's detection and differentiation from mild cognitive impairment.

A single intravenous ketamine infusion was safe and well-tolerated in older adults with mild cognitive impairment (MCI) and depression (MCI-D), with no serious adverse events (AEs) reported, a small ...